51. 全身性強皮症 Scleroderma Clinical trials / Disease details

臨床試験数 : 523 / 薬物数 : 608 - (DrugBank : 156) / 標的遺伝子数 : 114 - 標的パスウェイ数 : 215

2 trials found

diseases per page:

Showing 1 to 2 of 2 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04045743 (ClinicalTrials.gov)	July 19, 2019	27/7/2019	The Benefit of Bermekimab in Patients With Systemic Sclerosis	Clinical Efficacy of Inhibition of Organ Dysfunction Through Bermekimabin Systemic Sclerosis: A Proo ...	Scleroderma, Systemic	Drug: MABp1 (Bermekimab) OR Placebo;Drug: MABp1 (Bermekimab)	Hellenic Institute for the Study of Sepsis	NULL	Active, not recruiting	18 Years	N/A	All	20	Phase 2	Greece
2	EUCTR2018-004655-20-GR (EUCTR)	30/05/2019	31/01/2019	THE BENEFIT OF BERMEKIMAB IN PATIENTS WITH SYSTEMIC SCLEROSIS	CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMABIN SYSTEMIC SCLEROSIS: A PROO ...	CLINICAL EFFICACY OF INHIBITION OF ORGAN DYSFUNCTION THROUGH BERMEKIMABIN SYSTEMIC SCLEROSIS: A PROO ...	Product Name: BERMEKIMAB INN or Proposed INN: N/A Other descriptive name: BERMEKIMAB	HELLENIC INSTITUTE FOR THE STUDY OF SEPSIS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	20	Phase 2	Greece

First Previous1Next Last